Nationwide Survey Shows that Methicillin-Resistant Staphylococcus aureus Strains Heterogeneously and Intermediately Resistant to Vancomycin Are Not Disseminated throughout Japanese Hospitals
Open Access
- 1 December 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (12) , 4445-4451
- https://doi.org/10.1128/jcm.39.12.4445-4451.2001
Abstract
A total of 6,625 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates obtained from 278 hospitals throughout Japan were obtained between November and December 1997 and were examined for their sensitivities to vancomycin using Mueller Hinton (MH), brain heart infusion (BHI), agar plates, or the broth microdilution method. A concentrated inoculum of an MRSA strain or the use of highly enriched medium, such as BHI medium, allows an individual cell to grow on agar plates containing a vancomycin concentration greater than the MIC for the parent strain. However, cells of the colonies which grew on BHI agar plates containing the higher vancomycin concentrations did not acquire a level of vancomycin resistance greater than that of the parent strain and were not subpopulations of heterogeneously vancomycin-resistant MRSA. There was no significance in the fact that these colonies grew on the higher concentration of vancomycin: none showed stable resistance to vancomycin at a concentration above the MIC for the parent strain, and no cell from these colonies showed a relationship between the MIC and the ability of these colonies to grow on higher concentrations of vancomycin. The vancomycin MIC was not above 2 μg/ml for any of the cells originating from these colonies. No Mu3-type heterogeneously resistant MRSA strains, which constitutively produce subpopulations from MRSA clinical isolates with intermediate vancomycin resistance at a high frequency, were detected. There was a unipolar distribution of the MICs ranging from 0.25 to 2 μg of vancomycin/ml among the 6,625 MRSA clinical isolates, indicating that there was no Mu50-type intermediately vancomycin-resistant MRSA (MIC, 8 μg/ml by National Committee for Clinical Laboratory Standards criteria) among the clinical isolates, and there was no evidence of dissemination of Mu3-type MRSA heteroresistant to vancomycin.Keywords
This publication has 13 references indexed in Scilit:
- Practical Strategies for Detecting and Confirming Vancomycin-Intermediate Staphylococcus aureus : a Tertiary-Care Hospital Laboratory's ExperienceJournal of Clinical Microbiology, 2001
- Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureusEmerging Infectious Diseases, 2001
- A Spectrum of Changes Occurs in Peptidoglycan Composition of Glycopeptide-Intermediate Clinical Staphylococcus aureus IsolatesAntimicrobial Agents and Chemotherapy, 2001
- Contribution of a Thickened Cell Wall and Its Glutamine Nonamidated Component to the Vancomycin Resistance Expressed by Staphylococcus aureus Mu50Antimicrobial Agents and Chemotherapy, 2000
- Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.2000
- Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycinThe Lancet, 1999
- The Development of Vancomycin Resistance in a Patient with Methicillin-ResistantStaphylococcus aureusInfectionNew England Journal of Medicine, 1999
- Emergence of Vancomycin Resistance inStaphylococcus aureusNew England Journal of Medicine, 1999
- Staphylococcus aureus with Reduced Susceptibility to Vancomycin Isolated from a Patient with Fatal BacteremiaEmerging Infectious Diseases, 1999
- Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinThe Lancet, 1997